Israel OncoHost wins gold at the 2025 Merit Awards for Cancer Research Companies

Original source here

OncoHost , a technology company revolutionizing precision medicine to improve patient outcomes based in Binyamina and Cary, North Carolina, announced yesterday that it has won the Gold Medal in the 2025 Merit Awards for Business in the Research and Development category.

Presented annually by the Merit Awards, this program recognizes the world's most innovative companies and individuals driving measurable progress across industries. OncoHost was selected for its groundbreaking R&D on the PROphet® platform, an AI-powered proteomics solution that analyzes a patient's plasma proteome using bioinformatics and machine learning to deliver both predictive power and biological explainability.

“  Receiving the Gold Medal in Research and Development at the Merit Awards is a significant recognition of the ambitious scientific work being done at OncoHost ,” said Dr. Ofer Sharon, CEO of OncoHost. “  This recognition reinforces our mission: to equip oncologists with a predictive compass, ensuring every patient has the best chance of receiving the right treatment .”

OncoHost's R&D framework combines machine learning, proteomics, systems biology, and translational medicine. Its multidisciplinary team, comprised of theoretical physicists, molecular biologists, algorithm developers, and clinicians, works collaboratively to study mechanisms of treatment resistance and support the expansion of new clinical indications.

The company's flagship product, PROphetNSCLC™, is the first AI-based liquid biopsy proteomic test developed to guide first-line immunotherapy decisions in metastatic non-small cell lung cancer (NSCLC).

Beyond predicting response to immunotherapy, OncoHost is expanding the clinical utility of its platform with the development of PROphetirAE™, a tool designed to identify patients at risk for serious immune-related adverse events before treatment initiation.

Together, OncoHost's solutions promote a more personalized and proactive approach to care, tailoring treatment to the patient while helping to reduce preventable risks.

This award demonstrates OncoHost's continued progress in developing precision oncology.

With a growing clinical pipeline, a robust intellectual property portfolio, and a growing presence in the scientific literature, the company is focused on developing biomarker-based tools for more informed cancer management.

‍